Professor, Obstetrics and Gynecology, Washington University School of Medicine
Obstetrics & Gynecology
Dr. David G. Mutch, MD
David Mutch practices Obstetrics & Gynecology. He researched medicine at Washington University School of Medicine. He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Board Examiner", "Best Doctors in America list 10th year", "Dr. Neville Grant Award for Clinical Excellence", "Women's Health", "David G. Mutch Distinguished Alumni Scholarship", "St. Louis Magazine: Top Doctors", "Teacher of the Year", "Society of Gynecologic Oncologists Award Best paper for 1989 annual meeting", "Administrative Chief Resident", "Hugh M. Wilson Award in Radiology", "Fellow (FACOG)", "Top MD" and "Alpha Omega Alpha". David G. Mutch, MD is a published physician. He published 99 publications, including: 'Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer.'
Publications
- Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial Cancer.
- Intensity modulated radiation therapy for recurrent ovarian Cancer refractory to chemotherapy.
- Improved clinical trial enrollments for Uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center.
- Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.
- Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncolo...
- Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial AdenoCarcinoma: A Population-Based Analysis.
- Uterine Sarcoma, Version 1.2016.
- Ovarian Cancer in the United States: Contemporary patterns of care associated with improved survival.
- A Phase II Evaluation of Nintedanib (BIBF-1120) in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
- Neoadjuvant Chemotherapy Versus Primary Cytoreductive Surgery for Stage IV Uterine Serous Carcinoma.
- Pre-operative Assessment of Muscle Mass to Predict Surgical Complications and Prognosis in Patients With Endometrial Cancer.
- Polymerase ɛ (POLE) mutations in endometrial Cancer: Clinical outcomes and implications for Lynch syndrome testing.
- Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial Cancer.
- Etiology and Workup of Fevers in Gynecologic Oncology Patients.
- Update on prognostic markers for endometrial Cancer.
- Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women With High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study.
- Postradiation Damage to the Pelvic Girdle in Cervical Cancer Patients: Is Intensity-Modulated Radiation Therapy Safer Than Conventional Radiation?
- Racial disparities in uterine clear cell Carcinoma: a multi-institution study.
- Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage Uterine carcinosarcoma: A population-based analysis.
- Promoter Hypomethylation of EpCAM-Regulated Bone Morphogenetic Protein Gene Family in Recurrent Endometrial Cancer.
- Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Disclosing a Diagnosis of Cancer: Considerations Specific to Gynecologic Oncology Patients.
- High Frequency Strand Slippage Mutations in CTCF in MSI-Positive Endometrial Cancers.
- Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal Carcinoma.
- In vitro chemoresponse to cisplatin and outcomes in Cervical cancer.
- Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent Cervical cancer.
- Disparities in Ovarian Cancer Care Quality and Survival According to Race and Socioeconomic Status.
- Intestinal perforation in gynecologic oncology: do all patients benefit from surgical management?
- Frequent mutations in the RPL22 gene and its clinical and functional implications.
- Low yield of residual vulvar Carcinoma and dysplasia upon re-excision for close or positive margins.
- A review of iniparib in ovarian Cancer.
- Selumetinib in women with recurrent low-grade serous Carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
- Etiologic heterogeneity in endometrial Cancer: evidence from a Gynecologic Oncology Group trial.
- Lithium chloride and inhibition of glycogen synthase kinase 3? as a potential therapy for serous ovarian Cancer.
- The risk of lymph node metastasis with positive peritoneal cytology in endometrial Cancer.
- Positive peritoneal cytology is an independent risk-factor in early stage endometrial Cancer.
- Wilms' Tumor 1 Protein and Estrogen Receptor Beta Expression are Associated with Poor Outcomes in Uterine Carcinosarcoma.
- The utility and management of vaginal cytology after treatment for endometrial Cancer.
- BRCA1, TP53, and CHEK2 germline mutations in uterine serous Carcinoma.
- Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies.
- Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial Cancer.
- Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial Cancer: a conserved regulatory mechanism important in tumorigenesis?
- The Utility of Peritoneal Biopsy and Omentectomy in the Upstaging of Apparent Early Ovarian Cancer.
- Inferior vena cava filter placement in the gynecologic oncology patient: A 15-year institutional experience.
- Wound complications after gynecologic Cancer surgery.
- Lower uterine segment involvement is associated with poor outcomes in early-stage endometrioid endometrial Carcinoma.
- Pretreatment leukocytosis is an indicator of poor prognosis in patients with Cervical cancer.
- Aberrant Methylation of the X-Linked Ribosomal S6 Kinase RPS6KA6 (RSK4) in Endometrial Cancers.
- DICER1 expression and outcomes in endometrioid endometrial adenoCarcinoma.
- The effects of body mass index on complications and survival outcomes in patients with cervical Carcinoma undergoing curative chemoradiation therapy.
- Ovarian Cancer patient surveillance after curative-intent initial treatment.
- Cost-benefit of laparoscopic versus medical ovarian suppression in premenopausal breast Cancer.
- Clinical and pathologic features of vulvar intraepithelial neoplasia in premenopausal and PostMenopausal women.
- SGO future forward: Our greatest challenges are our greatest opportunities.
- Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced...
- Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial Carcinomas.
- Lymph node staging by positron emission tomography in Cervical cancer: relationship to prognosis.
- "Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian Cancer.
- Chemoradiation in locally advanced cervical Carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.
- Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial Cancer.
- The value of perioperative imaging in patients with Uterine sarcomas.
- A miR-200 microRNA cluster as prognostic marker in advanced ovarian Cancer.
- ATR mutation in endometrioid endometrial Cancer is associated with poor clinical outcomes.
- Long-term assessment of bladder and bowel dysfunction after radical hysterectomy.
- Ovarian Cancer: to screen or not to screen.
- Evaluation of new platinum-based treatment regimens in advanced-stage ovarian Cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
- Surveillance FDG-PET detection of Asymptomatic recurrences in patients with cervical cancer.
- Absence of MGMT promoter methylation in endometrial Cancer.
- Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal Cancer.
- Carboplatin dosing in obese women with ovarian Cancer: a Gynecologic Oncology Group study.
- Clear cell Carcinoma of the cervix: a multi-institutional review in the post-DES era.
- Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic Cancers.
- Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.
- CD83 gene polymorphisms increase susceptibility to human invasive Cervical cancer.
- Effect of a T0 radical hysterectomy specimen on survival for early stage Cervical cancer.
- Novel cytotoxic agents from an unexpected source: bile acids and Ovarian tumor apoptosis.
- Utility of parametrectomy for early stage Cervical cancer treated with radical hysterectomy.
- Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian Cancer.
- External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial Cancer.
- A multi-institutional review of outcomes of endometrial stromal sarcoma.
- Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial Carcinomas of the endometrioid type.
- Differential methylation hybridization array of endometrial Cancers reveals two novel Cancer-specific methylation markers.
- Excess of early onset multiple myeloma in endometrial Cancer probands and their relatives suggests common susceptibility.
- Evidence for heritable predisposition to epigenetic silencing of MLH1.
- Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial Cancer.
- Discussion: 'Accuracy of preoperative endometrial sampling' by Huang et al.
- How accurate is Pipelle sampling: a study by Huang et al.
- A vascular graft for endometrial Cancer groin recurrence.
- Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial Carcinoma.
- Getting the message out: RNA interference of human papillomavirus.
- Colposcopic accuracy of obstetrics and gynecology residents.
- Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal Cancer.
- Bevacizumab combination therapy in heavily pretreated, recurrent Cervical cancer.
- ASCO/SSO review of current role of risk-reducing surgery in common hereditary Cancer syndromes.
- CA-125 response in patients with recurrent ovarian or primary peritoneal Cancer treated with pegylated liposomal doxorubicin or topotecan.
- DNA mismatch repair and TP53 defects are early events in Uterine carcinosarcoma tumorigenesis.
- MLH3 mutation in endometrial Cancer.
- Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian Carcinoma: A retrospective analysis.
Schools
Washington University St Louis
Barnes Jewish Hospital
Duke University
Procedures Preformed
- Colpopexy
- Colporrhaphy
- Colposcopy
- Contraceptive Management
- View All
Conditions Treated
- Asymptomatic Post-Menopausal Status
- Atrophic Vaginitis
- Carcinoma in Situ
- Cervical Cancer
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Board Examiner
- “Best Doctors in America†list – 10th year
- Dr. Neville Grant Award for Clinical Excellence
- Women's Health
- David G. Mutch Distinguished Alumni Scholarship
- St. Louis Magazine: Top Doctors
- Teacher of the Year
- Society of Gynecologic Oncologists Award Best paper for 1989 annual meeting
- Administrative Chief Resident
- Hugh M. Wilson Award in Radiology
- Fellow (FACOG)
- Top MD
- Alpha Omega Alpha
Education
-
DUKE UNIVERSITY MEDICAL CENTER -
Washington University School of Medicine -
Washington University School of Medicine in St. Louis
Hospital
-
Barnes-Jewish Hospital -
St. Louis Children's Hospital
Drug Facts
| NPI NUMBER | 1518985217 | |
| NPPES Provider LastName | MUTCH | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Gynecological/Oncology | |
| Total Claim Count | 1465.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 197.0 | |
| Percent Opioid Claims | 13.45 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1518985217 |
| Last Name Of The Provider | MUTCH |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Kathy C. Maupin, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Shafia Bhutto, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Diane F. Merritt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David L. Gearhart, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Israel Zighelboim, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Amy H. Ruggeri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura A. Parks, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ming Shian Kao, MD |
|
|
Dr. Jodie Rai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jacqueline S. Turner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew Powell, MD |
|
|
Dr. Nishan H. Chobanian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karuna P. Murray, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Antonina Frolova, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kelle H. Moley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel M. Archer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie S. Rhee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher J. Kliethermes, MD
This Doctor is OpenDoctor Recommended.
|